New Delhi (ABC Live): The Government of India has approved M/s. Skymap Pharmaceuticals Private Limited as the strategic buyer for Indian Medicines Pharmaceutical Corporation Limited, commonly known as IMPCL.

At present, IMPCL functions as a Central Public Sector Enterprise under the Ministry of AYUSH. Moreover, it operates in the Ayurvedic and Unani medicine sector. Therefore, this transaction has both a disinvestment angle and a public-sector health-supply angle.

Accordingly, the Government has approved Skymap’s bid of ₹121,00,94,400, or about ₹121 crore. As a result, the transaction covers the sale of 100% equity shareholding along with transfer of management control.

Meanwhile, the Ministry of Finance announced the decision through a PIB release dated 26 May 2026. However, this report does not give a final valuation opinion.

Instead, this report records the Government decision, available asset data, public financial figures, and corporate information listed on public platforms. Moreover, ABC Live will need the reserve price, valuation report, latest audited financials, liabilities, and Share Purchase Agreement terms before publishing any final valuation review.

Therefore, readers should treat this article as a factual policy update, not as a valuation audit. Similarly, the uploaded draft follows this cautious reporting line and avoids a final valuation finding at this stage.

What the Government Has Approved

First, the Alternative Mechanism approved the transaction. Accordingly, this Group of Ministers acted under the authority of the Cabinet Committee on Economic Affairs.

According to the Government announcement, the Alternative Mechanism includes three ministers. Specifically, these are the Union Cabinet Minister for Road Transport and Highways, the Union Cabinet Minister for Finance, and the Union Minister of State with independent charge of AYUSH.

Further, the Government says the transaction followed a two-stage open and competitive bidding process. In addition, the process moved through a multi-layered consultation structure.

As a result, the process involved the Inter-Ministerial Group, the Core Group of Secretaries on Disinvestment, and the empowered Alternative Mechanism. Therefore, the Government has presented the sale as a structured strategic disinvestment process.

Transaction Snapshot

Subsequently, seven interested parties submitted Expressions of Interest. Thereafter, the Government shortlisted all seven as qualified bidders.

After that, the qualified bidders conducted due diligence. Meanwhile, the Ministry of Home Affairs gave security clearance.

Finally, the Government received two sealed financial bids by 20 January 2026. After evaluation, Skymap Pharmaceuticals emerged as the highest bidder at ₹121,00,94,400.

Although the Government has stated that Skymap’s bid stood above the reserve price, the PIB release does not disclose that reserve price. Therefore, readers should not treat the approved bid as a complete valuation finding.

What IMPCL Does

Historically, IMPCL came into existence on 12 July 1978. Since then, its core objective has been to manufacture and supply standardised Ayurvedic and Unani medicines.

Moreover, the Preliminary Information Memorandum issued for the disinvestment process describes IMPCL as a public-sector manufacturer in the Ayurvedic and Unani medicine sector. In addition, it records the company’s large product base.

Further, the PIM records that IMPCL supplies medicines to CGHS units, central research units, CCRAS, CCRUM, central and state government institutions, states under the National AYUSH Mission, and Jan Aushadhi Kendras.

Therefore, IMPCL is not only a government-owned company. Instead, it also forms part of India’s public-sector AYUSH medicine supply chain.

Shareholding Covered by the Sale

According to the latest Government announcement, the approved transaction covers 100% equity shareholding of IMPCL along with transfer of management control.

Meanwhile, the PIM records that the Government of India held 98.11% of IMPCL’s paid-up equity share capital. In addition, it records that Kumaon Mandal Vikas Nigam Limited, an undertaking of the Government of Uttarakhand, held the remaining 1.89%.

Moreover, the corrigendum to the EoI referred to the proposed strategic disinvestment of 100% stake in IMPCL held by the Government of India and KMVNL along with transfer of management control.

Thus, the announced transaction covers the full equity stake and management control. Moreover, it completes the ownership-transfer structure contemplated in the disinvestment process.

Available Public Asset Data of IMPCL

The public PIM gives asset and financial information for IMPCL up to 31 March 2022. Therefore, these figures help readers understand the available background.

However, these figures do not represent the final asset base used for the 2026 transaction. For that assessment, ABC Live needs the latest audited numbers and valuation documents.

Moreover, the PIM records IMPCL’s total campus area as 35.81 acres at Mohan, District Almora, Uttarakhand. In addition, it links this area to the revised lease deed executed with the State Infrastructure and Industrial Development Corporation of Uttarakhand Limited on 27 July 2023.

IMPCL Balance Sheet Extract Available in PIM

Because the PIM gives these figures in lakhs, this report converts them into crores for reader clarity.

Even so, ABC Live should use these figures only as publicly available background data. Therefore, it should not treat them as the final valuation basis for the 2026 sale.

Does the ₹121 Crore Bid Match IMPCL’s Public Asset Data?

The available public data allows only a limited comparison. Therefore, it does not allow a final valuation conclusion.

Based on the FY2022 PIM figures, Skymap’s approved bid of about ₹121 crore appears close to IMPCL’s FY2022 shareholder funds, or book net worth, of about ₹117.89 crore.

However, the bid remains lower than the FY2022 total asset figure of about ₹260.36 crore. As a result, the comparison raises a factual question, but it does not prove underpricing.

Limited Comparison With FY2022 Public Data

However, this comparison needs caution. Generally, a strategic disinvestment price does not depend only on total assets.

Instead, the buyer may also take over liabilities, operating risks, employee-related obligations, contractual commitments, investment needs, and business continuity duties.

Moreover, the Government has not yet disclosed the reserve price, valuation report summary, latest audited asset-liability position, or SPA obligations.

Therefore, ABC Live should not call the transaction undervalued or overvalued at this stage.

For now, the safer reporting line is:

The ₹121 crore bid appears close to IMPCL’s older publicly available book net worth figure. However, a final valuation comparison requires the reserve price, latest audited financials, asset valuation report, liabilities, and Share Purchase Agreement terms.

IMPCL Profit Position

A Lok Sabha reply dated 28 March 2025 stated that IMPCL was a profit-making CPSE. In addition, it stated that the Cabinet Committee on Economic Affairs approved IMPCL’s strategic disinvestment on 1 November 2017 as per the recommendation of NITI Aayog.

Net Profit Data

Furthermore, the same Lok Sabha answer stated that IMPCL had 74 permanent employees, 1 trainee, and 11 contractual employees as on 18 March 2025.

In addition, it recorded that the Government issued the PIM / EoI for IMPCL disinvestment in 2023 and received multiple EoIs.

Thus, the public record shows that IMPCL was not presented as a loss-making CPSE in that parliamentary reply. Therefore, the final valuation discussion should consider both financial and public-sector context once full documents become available.

Publicly Listed Details of Skymap Pharmaceuticals

Public corporate information platforms identify Skymap Pharmaceuticals Private Limited as a Delhi-registered pharmaceutical company with CIN U24233DL2006PTC150088.

In addition, they list its registered office as:

302, Narmada Block-5, Pocket D-6, Vasant Kunj, New Delhi – 110070

Directors Listed by Public Corporate Information Platforms

Further, public corporate information platforms such as Zauba, IndiaFilings, Tofler, and Credhive list Sanjay Gupta, Manish Garg, and Vinod Kumar Gupta as directors or signatories of Skymap Pharmaceuticals Private Limited.

However, ABC Live should describe them as “independently verified directors” only after confirming their directorship status through MCA-certified filings.

Until ABC Live checks MCA-certified filings, it should use the safer phrase:

directors listed by public corporate information platforms

As a result, readers receive useful first-level information. At the same time, the report avoids treating aggregator data as a final legal record.

Verification Note on Promoters and Ownership

For now, this report does not make a final statement on Skymap Pharmaceuticals’ promoter shareholding, beneficial ownership, financial strength, or group structure.

Instead, ABC Live should verify those details from MCA-certified records and transaction documents.

Therefore, ABC Live should avoid using the word “promoters” for Skymap’s ownership structure unless MCA records or transaction documents confirm promoter shareholding and beneficial ownership.

What Is Still Not Public

The PIB release confirms the Government decision and the approved bid amount. However, it does not disclose several details needed for a final asset-to-price assessment.

Therefore, ABC Live should wait for these documents before it reaches any final conclusion on whether the ₹121 crore price reflects IMPCL’s public and commercial value.

ABC Live Reporting Line

The Government of India has approved M/s. Skymap Pharmaceuticals Private Limited as the strategic buyer for Indian Medicines Pharmaceutical Corporation Limited for about ₹121 crore. Moreover, IMPCL is a Ministry of AYUSH CPSE that manufactures standardised Ayurvedic and Unani medicines. Public PIM data shows that IMPCL had total assets of ₹260.36 crore and shareholder funds of about ₹117.89 crore as on 31 March 2022. Therefore, the approved bid is close to the older book net worth figure but lower than the older total asset figure. However, a final valuation assessment requires the reserve price, valuation report, latest audited financials, liabilities, and Share Purchase Agreement terms. In addition, public corporate information platforms list Sanjay Gupta, Manish Garg, and Vinod Kumar Gupta as directors of Skymap Pharmaceuticals Private Limited. Even so, ABC Live should treat them as independently verified directors only after checking MCA-certified filings.

Why ABC Live Is Not Giving a Final Valuation Opinion Yet

ABC Live is not giving a final opinion on whether the transaction is underpriced or fairly priced because public data remains incomplete.

At present, the public record confirms some basic facts. However, it still lacks several valuation-critical documents.

Therefore, this distinction matters. ABC Live can publish a factual report now. However, it should wait for more documents before publishing a full valuation audit.

Sources and Verification

This report relies on the PIB release dated 26 May 2026, the IMPCL Preliminary Information Memorandum / EoI documents, DIPAM-linked disinvestment material, the Lok Sabha reply dated 28 March 2025, and public corporate information platforms for Skymap Pharmaceuticals.

However, ABC Live should verify Skymap Pharmaceuticals’ corporate details from MCA-certified filings before it publishes any detailed ownership, promoter, or financial strength analysis.

Final Editorial Note

The Government has approved the strategic disinvestment of IMPCL to Skymap Pharmaceuticals Private Limited for about ₹121 crore. Therefore, the transaction covers 100% equity shareholding and transfer of management control.

Public FY2022 PIM data shows IMPCL’s total assets at about ₹260.36 crore and shareholder funds at about ₹117.89 crore. Therefore, the approved bid appears close to the older book net worth figure.

However, it remains lower than the older total asset figure. Even so, this comparison is only preliminary.

As a result, a final assessment requires the Government’s reserve price, valuation report, latest audited asset-liability position, SPA terms, employee safeguards, business continuity obligations, and MCA-certified details of the strategic buyer.

For now, ABC Live treat this as a factual policy report, not as a final valuation judgment.

Also Read ABC Report

Explained: How India Can Benefit from Integrated Pharmacology